Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Postoperative ctDNA-based Minimal Residual Disease Detection for Resected Pancreatic Adenocarcinoma: A Prospective Observational Cohort Study

NCT05479708 is registered in ClinicalTrials.gov with BAIYONG SHEN as lead sponsor.

NCT NCT05479708
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05479708 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Postoperative ctDNA-based Minimal Residual Disease Detection for Resected Pancreatic Adenocarcinoma: A Prospective Observational Cohort Study
Lead sponsor
BAIYONG SHEN
Phase
Observational
Overall status
Active, not recruiting
Start date
August 9, 2023
Completion date
August 31, 2028
Enrollment
150 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer resectable